Search Results - "McMillan, A K"

Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial by Patel, B, Kirkwood, A A, Dey, A, Marks, D I, McMillan, A K, Menne, T F, Micklewright, L, Patrick, P, Purnell, S, Rowntree, C J, Smith, P, Fielding, A K

“…Safety and efficacy data on pegylated asparaginase (PEG-ASP) in adult acute lymphoblastic leukaemia (ALL) induction regimens are limited. The UK National…”
Get full text

Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial by McMillan, A.K., Phillips, E.H., Kirkwood, A.A., Barrans, S., Burton, C., Rule, S., Patmore, R., Pettengell, R., Ardeshna, K.M., Lawrie, A., Montoto, S., Paneesha, S., Clifton-Hadley, L., Linch, D.C.

“…Outcomes for patients with high-risk diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy are suboptimal but, to date, no alternative regimen…”
Get full text

Dose–response between frequency of interruption of sedentary time and fasting glucose, the dawn phenomenon and night‐time glucose in Type 2 diabetes by Paing, A. C., McMillan, K. A., Kirk, A. F., Collier, A., Hewitt, A., Chastin, S. F. M.

“…Aim To explore the dose–response between frequency of interruption of sedentary time and basal glucose (fasting glucose, the dawn phenomenon and night‐time…”
Get full text

The Place of High-Dose BEAM Therapy and Autologous Bone Marrow Transplantation in Poor-Risk Hodgkin's Disease. A Single-Center Eight-Year Study of 155 Patients by Chopra, R., McMillan, A.K., Linch, D.C., Yuklea, S., Taghipour, G., Pearce, R., Patterson, K.G., Goldstone, A.H.

“…Although high-dose chemotherapy and autologous bone marrow transplantation (ABMT) are increasingly being used for the treatment of relapsed and resistant…”
Get full text

IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma by Fox, C. P., McMillan, A. K., Bishton, M. J., Haynes, A. P., Russell, N. H.

“…Summary Two commonly used chemotherapy regimens for lymphoma salvage therapy were compared: ICE (ifosphamide, carboplatin and etoposide) ± rituximab and IVE…”
Get full text

Replacing procarbazine with dacarbazine in escalated BEACOPP reduces clinical toxicity with no loss of efficacy yet protects stem cells from excess somatic mutational damage by Santarsieri, A., Mitchell, E., Sanghvi, R., Lee‐Six, H., Sturgess, K., Brice, P., Menne, T., Osborne, W., Creasey, T., Ardesnhna, K. M., Behan, S., Bhuller, K., Booth, S., Chavda, N. D., Collins, G., Culligan, D., Cwynarski, K., Davies, A., Downing, A., Dutton, D., Furtado, M., Gallop‐Evans, E., Hodson, A., Hopkins, D., Hsu, H., Iyengar, S., Jones, S. G., Linton, K. M., Lomas, O. C., Martinez‐Calle, N., Mathur, A., McKay, P., Nagumantry, S. K., Phillips, E. H., Phillips, N., Rudge, J. F., Shah, N. K., Stafford, G., Sternberg, A., Trickey, R., Uttenthal, B. J., Wetherall, N., Zhang, X., McMillan, A. K., Rahbari, R., Stratton, M., Laurenti, E., Borchmann, S., Borchmann, P., Campbell, P. J., Follows, G. A.

Get full text

MODIFICATION OF ESCALATED BEACOPP WITH DACARBAZINE SUBSTITUTION REDUCES TOXICITY WHILE MAINTAINING EFFICACY FOR THE TREATMENT OF ADVANCED STAGE HODGKIN LYMPHOMA by Santarsieri, A., Sturgess, K., Brice, P., Menne, T. F., Osborne, W., Creasey, T., Ardeshna, K. M., Behan, S., Bhuller, K., Booth, S., Collins, G. P., Cwynarski, K., Furtado, M., Iyenga, S., Jones, S. G., O'Mahony, D., Martinez‐Calle, N., McKay, P., Nagumantry, S. K., Rudge, J. F., Shah, N., Stafford, G., Sternberg, A., Uttenthal, B. J., McMillan, A. K., Follows, G. A.

Get full text

Era-by-era improvement in survival for elderly patients with Hodgkin lymphoma; outcome data from a large population-based cohort by Bishton, M.J., Hubbard, R., Witherall, R., Jones, S.G., Richardson, F., James, E.J., Sovani, V., Bessell, E.M., Haynes, A.P., McMillan, A.K., Fox, C.P.

Get full text

Successful Treatment of Refractory Hodgkin's Disease by High-Dose Combination Chemotherapy and Autologous Bone Marrow Transplantation by Gribben, J.G., Linch, D.C., Singer, C.R.J., McMillan, A.K., Jarrett, Margaret, Goldstone, A.H.

“…Forty-four patients with refractory Hodgkin's disease were treated with high-dose combination chemotherapy follwed by autologous bone marrow rescue. Twenty-two…”
Get full text

Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy by Gribben, J G, Goldstone, A H, Linch, D C, Taghipour, G, McMillan, A K, Souhami, R L, Earl, H, Richards, J D

“…We commenced a study in September 1981 to investigate the role of high-dose combination chemotherapy in the management of patients with non-Hodgkin's lymphomas…”
Get more information

Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease by Chopra, R, Linch, D C, McMillan, A K, Blair, S, Patterson, K G, Moir, D, Richards, J D, Cervi, P, Kinsey, S, Goldstone, A H

“…High dose chemotherapy and autologous bone marrow transplantation (ABMT) is an effective form of salvage therapy in patients with relapsed or resistant…”
Get more information

Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British autograft group experience by Chopra, R, Goldstone, A H, McMillan, A K, Powles, R, Smith, A G, Prentice, H G, Reid, C, Marcus, R, Bell, A, Milligan, D

“…The results in 34 adult patients with acute myeloid leukemia (AML) who have undergone autologous bone marrow transplantation (ABMT) using busulfan and…”
Get more information

High-Dose Chemotherapy and Autologous Bone Marrow Transplantation in Acute Myeloid Leukemia by McMillan, A.K., Goldstone, A.H., Linch, D.C., Gribben, J.G., Patterson, K.G., Richards, J.D.M., Franklin, I., Boughton, B.J., Milligan, D.W., Leyland, M., Hutchison, R.M., Newland, A.C.

“…For younger patients with acute myeloid leukemia (AMD, an allogeneic transplant from a matched sibling may afford the best chance of cure. In patients who are…”
Get full text

Successful pregnancies in women following single autotransplant for acute myeloid leukemia with a chemotherapy ablation protocol by Salooja, N, Chatterjee, R, McMillan, A K, Kelsey, S M, Newland, A C, Milligan, D W, Franklin, I M, Hutchinson, R M, Linch, D C, Goldstone, A H

“…Of 30 women surviving a minimum of 18 months following treatment for AML with a high-dose chemotherapy regimen with autologous bone marrow transplantation…”
Get more information

The place of high-dose therapy with haemopoietic stem cell transplantation in relapsed and refractory Hodgkin's disease by Goldstone, A H, McMillan, A K

“…Conventional salvage therapy in Hodgkin's disease is appropriate in patients who relapse after a first complete remission of greater than one year many of whom…”
Get more information

Autologous bone marrow transplantation for non-Hodgkin's lymphoma by McMillan, A K, Goldstone, A H

“…Autologous bone marrow transplantation (ABMT) is now so widely applied in the treatment of relapsed high- and intermediate-grade non-Hodgkin's lymphoma (NHL)…”
Get more information

Conceptual problems in relation to dose escalation in the first remission of Hodgkin's disease by Goldstone, A H, McMillan, A K

“…Autologous bone marrow transplantation (ABMT) is now widely used as salvage therapy in Hodgkin's disease but its value will have to be finally proved by the…”
Get more information

Detection and significance of bone marrow infiltration at the time of autologous bone marrow transplantation in Hodgkin's disease by Chopra, R, Wotherspoon, A C, Blair, S, McMillan, A K, Mills, W, Fielding, A K, Linch, D C, Goldstone, A H

“…Bilateral iliac crest biopsies were performed at the time of bone marrow (BM) harvest in patients with poor-risk Hodgkin's disease (HD) undergoing autologous…”
Get more information

A comparison of the outcome of ABMT in first remission acute myeloid and lymphoblastic leukemia in a single centre by McMillan, A K, Goldstone, A H, Chopra, R, Linch, D C

Get more information

The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial by Marks, David I, Moorman, Anthony V, Chilton, Lucy, Paietta, Elisabeth, Enshaie, Amir, DeWald, Gordon, Harrison, Christine J, Fielding, Adele K, Foroni, Letizia, Goldstone, Anthony H, Litzow, Mark R, Luger, Selina M, McMillan, Andrew K, Racevskis, Janis, Rowe, Jacob M, Tallman, Martin S, Wiernik, Peter, Lazarus, Hillard M

“…The biology and outcome of adult t(4;11)(q21;q23)/MLL-AFF1 acute lymphoblastic leukemia are poorly understood. We describe the outcome and delineate prognostic…”
Get full text